WILMINGTON, DE — Incyte Corporation (Nasdaq: INCY) will release its third-quarter 2026 financial results on October 29, providing investors with an update on the biopharmaceutical company’s performance across its hematology, oncology and inflammation businesses.
The Wilmington-based company said its earnings report will be issued at 7 a.m. Eastern Time, followed by a conference call and webcast at 8 a.m.
Investors can access the conference call by dialing 877-407-3042 from the United States or 201-389-0864 internationally, using conference identification number 13763051.
A live webcast, accompanied by presentation slides, will be available at Investor.Incyte.com.
The company will provide a telephone replay for 30 days following the call. U.S. callers can access the replay at 877-660-6853, while international callers can dial 201-612-7415, using the same conference identification number.
The webcast replay will remain available for 90 days.
Incyte develops and commercializes medicines across hematology, oncology, and inflammation and autoimmunity, with an established pharmaceutical portfolio and additional treatments in development.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.